SRP in Combination With PERIOWAVE in Comparison to SRP Alone in Chronic Periodontitis
Launched by ONDINE RESEARCH LABORATORIES · Feb 24, 2006
Trial Information
Current as of May 09, 2025
Unknown status
Keywords
ClinConnect Summary
Extensive research has shown that lethal photosensitization with low levels of laser light is an effective method of killing numerous types of organisms. This therapy avoids the use of antibiotics along with their potential side effects. The initial application of this therapy to the oral cavity is particularly appropriate since the therapy can be applied topically either in a specific or general fashion, killing is immediate and resistance is unlikely as it is free radical-mediated. In addition, the disease states being treated (gingivitis \& periodontitis) are highly prevalent and associa...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. The subject is capable of giving informed consent
- • 2. Subject is willing to sign a consent form
- • 3. Adult male or female ≥ the age of 18
- • 4. Having been diagnosed with chronic periodontitis
- • 5. \>18 fully erupted teeth
- • 6. Has had no periodontal instrumentation in the four months prior to the initiation of study treatment
- • 7. Subject has at least 4 sites with pocket depth of 6-9 mm in at least two quadrants of the mouth.
- • 8. Subject is willing and able to return for treatment and evaluation procedures scheduled throughout the course of this clinical study
- Exclusion Criteria:
- • 1. Is pregnant or nursing or who plans to become pregnant in the next 4 months
- • 2. Having significant liver disease by subject report
- • 3. Having an active malignancy of any type by subject report
- • 4. Having chronic disease or diminished mental capacity that would mitigate the ability to comply with the protocol
- • 5. Having any significant chronic disease (either acute or chronic) with concomitant oral manifestations that in the opinion of the investigator would interfere with evaluation of safety or efficacy of PerioWave®
- • 6. Having an active periapical abscess or periodontal abscess
- • 7. Treatment with antibiotics with in the 1-month period prior to beginning the study or any systemic condition which requires antibiotic coverage for routine periodontal procedures (e.g. heart conditions, joint replacements, etc) by report of the subject
- • 8. History of acute necrotizing ulcerative gingivitis
- • 9. Known allergy to Methylene Blue
- • 10. Has glucose-6-phosphate dehydrogenase (G6PD) deficiency by subject report
- • 11. Currently uses anti-coagulant therapy at therapeutic doses
- • 12. Currently uses photosensitizing medications
- • 13. Participated in investigational treatment in the last 30 days or expectation for using a separate investigational treatment during the time of the study
About Ondine Research Laboratories
Ondine Research Laboratories is a leading clinical trial sponsor dedicated to advancing innovative therapeutic solutions in the field of healthcare. With a strong emphasis on research and development, the organization specializes in pioneering treatments that address unmet medical needs, utilizing cutting-edge technology and evidence-based methodologies. Committed to rigorous clinical standards and ethical practices, Ondine collaborates with a network of healthcare professionals and institutions to ensure the successful execution of clinical trials, ultimately aiming to enhance patient outcomes and improve quality of life. Their expertise spans multiple therapeutic areas, reflecting a holistic approach to patient care and disease management.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
London, , United Kingdom
Patients applied
Trial Officials
Nikos Donos, DDS, MS, PhD
Principal Investigator
University College London, Eastman Dental Institute
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials